JP2021063120A5 - - Google Patents

Download PDF

Info

Publication number
JP2021063120A5
JP2021063120A5 JP2021001547A JP2021001547A JP2021063120A5 JP 2021063120 A5 JP2021063120 A5 JP 2021063120A5 JP 2021001547 A JP2021001547 A JP 2021001547A JP 2021001547 A JP2021001547 A JP 2021001547A JP 2021063120 A5 JP2021063120 A5 JP 2021063120A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
cancer
administered
coxsackie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021001547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021063120A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021063120A publication Critical patent/JP2021063120A/ja
Publication of JP2021063120A5 publication Critical patent/JP2021063120A5/ja
Pending legal-status Critical Current

Links

JP2021001547A 2014-02-27 2021-01-07 癌を処置するための併用方法 Pending JP2021063120A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014900647A AU2014900647A0 (en) 2014-02-27 Combination method for treatment of cancer
AU2014900647 2014-02-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016554571A Division JP6857498B2 (ja) 2014-02-27 2015-02-27 癌を処置するための併用方法

Publications (2)

Publication Number Publication Date
JP2021063120A JP2021063120A (ja) 2021-04-22
JP2021063120A5 true JP2021063120A5 (enExample) 2021-06-10

Family

ID=54008051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554571A Expired - Fee Related JP6857498B2 (ja) 2014-02-27 2015-02-27 癌を処置するための併用方法
JP2021001547A Pending JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016554571A Expired - Fee Related JP6857498B2 (ja) 2014-02-27 2015-02-27 癌を処置するための併用方法

Country Status (9)

Country Link
US (3) US20170000832A1 (enExample)
EP (2) EP3441084A1 (enExample)
JP (2) JP6857498B2 (enExample)
KR (1) KR102407019B1 (enExample)
CN (1) CN107073099B (enExample)
AU (2) AU2015222685A1 (enExample)
CA (1) CA2940570A1 (enExample)
SG (2) SG10201801562PA (enExample)
WO (1) WO2015127501A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176468A1 (en) 2005-12-02 2011-12-29 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR102407019B1 (ko) * 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
CN108697788A (zh) * 2015-10-15 2018-10-23 杜克大学 组合治疗
JP2019508063A (ja) 2016-01-27 2019-03-28 オンコラス, インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018085461A1 (en) * 2016-11-01 2018-05-11 Dnatrix, Inc. Combination therapy for treatment of brain cancers
JP2020516601A (ja) * 2017-04-07 2020-06-11 ホオキパ バイオテック ジーエムビーエイチ 固形腫瘍を治療するためのアレナウイルス粒子
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス, インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
KR102093623B1 (ko) * 2018-08-17 2020-03-26 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11230189B2 (en) 2019-03-29 2022-01-25 Honda Motor Co., Ltd. System and method for application interaction on an elongated display screen
AR120794A1 (es) 2019-12-20 2022-03-16 Merck Sharp & Dohme Composiciones purificadas de enterovirus y métodos de purificación con cromatografía de afinidad con glutatión

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
ATE411809T1 (de) 1993-04-30 2008-11-15 Wellstat Biologics Corp Zusuammensetzungen zur behandlung von krebs mittels viren
ES2210273T5 (es) 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. Virus con arn de cadena negativa no segmentado recombinante infeccioso.
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
CN1200037A (zh) 1995-10-17 1998-11-25 韦恩州立大学 鸡白细胞介素-15及其用途
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
JP2000517194A (ja) 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
CA2302867A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
CA2305269C (en) 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999064570A1 (en) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
AU4971500A (en) 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
AU5998400A (en) 1999-07-14 2001-01-30 Mount Sinai School Of Medicine Of The City University Of New York, The In vitro reconstitution of segmented negative-strand rna viruses
AU7607900A (en) 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ES2246314T3 (es) 2000-01-20 2006-02-16 Universitat Zurich Institut Fur Medizinische Virologie Administracion intratumoral de moleculas desnudas de acido nucleico que codifican il-12.
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
WO2002102404A1 (en) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Uses of cytokines
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
JPWO2003102183A1 (ja) 2002-06-03 2005-09-29 株式会社ディナベック研究所 抗体をコードするパラミクソウイルスベクターおよびその利用
US7971030B2 (en) 2002-08-07 2011-06-28 Mmagix Technology Limited Method for using multiple processing resources which share multiple co-processor resources
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
ATE516305T1 (de) 2004-02-27 2011-07-15 Inst Nat Sante Rech Med Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
WO2005087931A1 (en) 2004-03-11 2005-09-22 Virotarg Pty Ltd Modified oncolytic viruses
WO2006017914A1 (en) 2004-08-20 2006-02-23 Viralytics Limited Methods and compositions for treatment of hematologic cancers
ZA200702269B (en) * 2004-08-20 2008-09-25 Viralytics Ltd Methods and compositions for treatment of hematologic cancers
NZ591733A (en) 2004-11-12 2012-10-26 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme
US20080160031A1 (en) 2005-01-17 2008-07-03 Viralytics Limited Method and Composition for Treatment of Neoplasms
EP1899364B2 (en) 2005-05-17 2024-10-30 University of Connecticut Compositions and methods for immunomodulation in an organism
US20090214590A1 (en) 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
JP2009504687A (ja) * 2005-08-31 2009-02-05 オンコリティクス バイオテク,インコーポレーテッド 新生物に関する免疫系による認識のインビボでの増強のための、腫瘍崩壊ウイルスおよび免疫賦活剤による処置
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
SG176468A1 (en) 2005-12-02 2011-12-29 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007084342A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008011726A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2173378T3 (da) 2007-06-27 2014-05-12 Admune Therapeutics Llc Komplekser af il-15 og il-15ralfa og anvendelser deraf
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
EP2424887B1 (en) 2009-04-30 2015-09-30 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inducible interleukin-12
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
ES2598005T3 (es) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
RU2592544C2 (ru) 2009-08-21 2016-07-20 Мериал, Инк. Способ получения рекомбинантного вирусного вектора apmv-8
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
EP2550298B1 (en) 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2012000188A1 (en) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
EP4385570A3 (en) 2010-09-21 2024-09-11 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012322999B2 (en) 2011-10-11 2017-08-10 Universitat Zurich Prorektorat Mnw Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
BR112014018331A8 (pt) 2012-01-25 2017-07-11 Univ Texas Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
WO2014047350A1 (en) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
CN109395064A (zh) 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
AU2014284100A1 (en) 2013-06-17 2015-12-24 Viralytics Limited Methods for the treatment of bladder cancer
EP3659622A1 (en) 2013-08-08 2020-06-03 Cytune Pharma Combined pharmaceutical composition
PL3444271T3 (pl) 2013-08-08 2022-03-07 Cytune Pharma Modulokiny oparte na il-15 i domenie sushi il-15ralfa
EA202191926A3 (ru) 2013-09-03 2022-01-31 Медиммун Лимитед Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии
KR102407019B1 (ko) * 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016048903A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
AU2015360736A1 (en) 2014-12-09 2017-06-01 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技(北京)有限公司 一种用于术前介入放疗治疗肿瘤的化合物
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用

Similar Documents

Publication Publication Date Title
JP2021063120A5 (enExample)
Jin et al. Immunogenic cell death-based cancer vaccines
Yasinjan et al. Immunotherapy: a promising approach for glioma treatment
JP7631485B2 (ja) キメラポックスウイルス組成物及びその使用
Wang et al. Cancer radiosensitizers
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
JP2017506662A5 (enExample)
JP2019501204A5 (enExample)
JP2017533912A5 (enExample)
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP2005524631A5 (enExample)
RU2018111529A (ru) Комбинированная терапия для лечения рака
JP2011157399A5 (enExample)
Ding et al. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: trends and challenges
RU2017134148A (ru) Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства
Lüke et al. Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin’s disease
JP2021501150A5 (enExample)
JP2017537927A5 (enExample)
Hsieh et al. Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma
JP2009510165A5 (enExample)
CN112691119A (zh) 一种抗肿瘤组合物及其应用和抗肿瘤药物
Huang et al. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model
Sobti et al. Advanced Therapeutic Approaches in Cancer Therapy
JPWO2020223702A5 (enExample)
Luo et al. Research advances in chimeric antigen receptor-modified T-cell therapy